Cannabics Pharmaceuticals unveils new dosage of 5mg THC Cannabis capsule

Cannabics Pharmaceuticals chief scientist Eyal Ballan stated, "Our mission is to find the right balance between efficacy on the one hand and the elimination of undesired psychoactive effects on other."

The Cannabics 5mg THC capsule is currently being evaluated by the company in a clinical study as a palliative treatment, which is conducted by the oncology department at the prestigious Rambam Medical Center in northern Israel and under strict regulations of the Ministry of Health, by whom Cannabics Pharmaceuticals has been licensed since 2014.

The study is taking place in Israel, it is fully registered with the US NIH under "Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients", Identifier NCT02359123, and may be found at https://clinicaltrials.gov/ct2/show/NCT02359123

Itamar Borochov, CEO of Cannabics Pharmaceuticals, said: "The majority of our cancer trial patients have no previous experience with Cannabis, hence this recalibration of the THC level may be more amenable. We believe there is a significant potential medical market for our 5mg THC capsule in countries that have now instituted medical cannabis regulations."